Hylton NM - Search Results

1

Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.

Magbanua MJM, Ahmed Z, Sayaman RW, Brown Swigart L, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Perlmutter J, Pohlmann P, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ. Magbanua MJM, et al. Among authors: hylton nm. Clin Cancer Res. 2024 Jun 3;30(11):2444-2451. doi: 10.1158/1078-0432.CCR-23-2928. Clin Cancer Res. 2024. PMID: 38470545 Free PMC article.

2

Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging.

Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E. Esserman L, et al. J Clin Oncol. 1999 Jan;17(1):110-9. doi: 10.1200/JCO.1999.17.1.110. J Clin Oncol. 1999. PMID: 10458224

3

Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability.

Kinkel K, Helbich TH, Esserman LJ, Barclay J, Schwerin EH, Sickles EA, Hylton NM. Kinkel K, et al. Among authors: hylton nm. AJR Am J Roentgenol. 2000 Jul;175(1):35-43. doi: 10.2214/ajr.175.1.1750035. AJR Am J Roentgenol. 2000. PMID: 10882243

4

Integration of breast imaging into cancer management.

Esserman LJ, Wolverton D, Hylton N. Esserman LJ, et al. Curr Oncol Rep. 2000 Nov;2(6):572-81. doi: 10.1007/s11912-000-0112-y. Curr Oncol Rep. 2000. PMID: 11122895 Review.

5

Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma.

Esserman L, Hylton N, George T, Weidner N. Esserman L, et al. Breast J. 1999 Jan;5(1):13-21. doi: 10.1046/j.1524-4741.1999.005001013.x. Breast J. 1999. PMID: 11348250

6

MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer.

Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N. Esserman L, et al. Ann Surg Oncol. 2001 Jul;8(6):549-59. doi: 10.1007/s10434-001-0549-8. Ann Surg Oncol. 2001. PMID: 11456056

7

Magnetic resonance imaging for primary breast cancer management: current role and new applications.

Esserman L, Wolverton D, Hylton N. Esserman L, et al. Endocr Relat Cancer. 2002 Jun;9(2):141-53. doi: 10.1677/erc.0.0090141. Endocr Relat Cancer. 2002. PMID: 12121836 Review.

8

Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy.

Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Partridge SC, et al. Among authors: hylton nm. AJR Am J Roentgenol. 2002 Nov;179(5):1193-9. doi: 10.2214/ajr.179.5.1791193. AJR Am J Roentgenol. 2002. PMID: 12388497

9

Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity.

Hwang ES, Kinkel K, Esserman LJ, Lu Y, Weidner N, Hylton NM. Hwang ES, et al. Among authors: hylton nm. Ann Surg Oncol. 2003 May;10(4):381-8. doi: 10.1245/aso.2003.03.085. Ann Surg Oncol. 2003. PMID: 12734086

10

MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival.

Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, Rugo HS, Hwang ES, Ewing CA, Hylton NM. Partridge SC, et al. Among authors: hylton nm. AJR Am J Roentgenol. 2005 Jun;184(6):1774-81. doi: 10.2214/ajr.184.6.01841774. AJR Am J Roentgenol. 2005. PMID: 15908529

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

191 results

Search Page

Filters